Physician profile
Gery Florek
NPI 1205919677
$66,885.28
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,303 · 2020: $28K · 2021: $37K · 2022: $231 · 2024: $70.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22,545.14 | 2019-2021 | |
| Abbvie INC. | $18,795.54 | 2020-2024 | |
| Allergan, INC. | $9,353.30 | 2019-2021 | |
| Amgen INC. | $6,509.06 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $4,471.40 | 2020-2021 | |
| Biogen, INC. | $625.94 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $499.59 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $462.96 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $447.41 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $378.56 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $373.23 | 2019-2021 | |
| Lundbeck LLC | $360.47 | 2020-2021 | |
| Eisai INC. | $263.08 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $220.82 | 2019-2020 | |
| Ucb, INC. | $199.41 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $165.66 | 2021 | |
| Assertio Therapeutics, INC. | $119.69 | 2019-2020 | |
| Emd Serono, INC. | $116.66 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $114.07 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $112.11 | 2021 | |
| Sk Life Science, INC. | $109.64 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $105.83 | 2019 | |
| Avanir Pharmaceuticals, INC. | $76.45 | 2019 | |
| Novocure INC. | $73.51 | 2022 | |
| Genzyme Corporation | $71.54 | 2019-2020 | |
| Zyla Life Sciences, INC. | $58.45 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $57.31 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $47.65 | 2020-2021 | |
| Greenwich Biosciences, INC. | $46.90 | 2021 | |
| Promius Pharma LLC | $34.63 | 2019 | |
| Tanabe Pharma America, INC. | $21.76 | 2019 | |
| Celgene Corporation | $19.57 | 2021 | |
| Genentech USA, INC. | $16.06 | 2021 | |
| Almatica Pharma LLC | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gery Florek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.